The earnings call presented a mix of positive developments and challenges. While VITAS showed some growth in admissions and revenue, the Florida Medicare cap issue and Roto-Rooter's revenue struggles, along with the reduced earnings guidance, highlight significant challenges. The overall sentiment of the call reflects balanced highlights and lowlights.

Company Guidance

During the Chemed Corporation's Second Quarter 2025 Earnings Conference Call, the company provided detailed guidance on its financial outlook for the remainder of the year. VITAS is expected to see a full-year 2025 revenue increase of 7.5% to 8.5% compared to 2024, with an adjusted EBITDA margin projected to be between 18.2% and 18.7%. The company anticipates $28.2 million in Medicare Cap billing limitations for 2025, with $19 million attributed to the Florida combined program. Roto-Rooter's revenue is forecasted to grow by 1.25% to 1.75% in 2025, with an adjusted EBITDA margin expected to be between 23.5% and 24.5%. The full-year 2025 earnings per diluted share are estimated to be in the range of $22 to $22.30, assuming an effective tax rate of 25.3% and a diluted share count of 14.7 million shares. Chemed's previously issued 2025 guidance was $24.95 to $25.45 per diluted share, compared to the reported adjusted earnings per diluted share of $23.13 in 2024.

VITAS Admissions Increase

Admissions at VITAS increased by 4.9% in the second quarter of 2025 compared to the same period in 2024, excluding transfers from the previous year acquisition.

VITAS Revenue Growth

VITAS net revenue increased by 5.8% to $396.2 million in the second quarter of 2025, driven by a 6.1% increase in days of care and a 4.2% increase in Medicare reimbursement rates.

Roto-Rooter Commercial Revenue Increase

Roto-Rooter branch commercial revenue increased by 4.4% in the second quarter of 2025, driven by a 24.4% increase in excavation and an 11.7% increase in water restoration.

Chemed (CHE) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

CHE Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Oct 29, 2025	2025 (Q3)	5.36 / -	5.64	―	―	―
Jun 30, 2025	2025 (Q2)	5.12 / 4.27	5.47	-21.94% (-1.20)	―	―
Apr 23, 2025	2025 (Q1)	5.55 / 5.63	5.2	8.27% (+0.43)
Feb 26, 2025	2024 (Q4)	6.78 / 6.83	6.6	3.48% (+0.23)
Oct 29, 2024	2024 (Q3)	5.64 / 5.64	5.32	6.02% (+0.32)
Jul 24, 2024	2024 (Q2)	5.59 / 5.47	4.71	16.14% (+0.76)
Apr 24, 2024	2024 (Q1)	5.48 / 5.20	4.82	7.88% (+0.38)
Feb 27, 2024	2023 (Q4)	6.25 / 6.60	5.39	22.45% (+1.21)	―
Oct 25, 2023	2023 (Q3)	4.90 / 5.32	4.74	12.24% (+0.58)	―
Jul 26, 2023	2023 (Q2)	5.09 / 4.71	4.84	-2.69% (-0.13)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

CHE Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Jun 30, 2025	$486.26	$483.25	-0.62%
Apr 23, 2025	$584.14	$545.55	-6.61%
Feb 26, 2025	$544.56	$584.80	+7.39%
Oct 29, 2024	$607.33	$533.63	-12.14%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Chemed Corporation (CHE) report earnings?

Chemed Corporation (CHE) is schdueled to report earning on Oct 29, 2025, After Close (Confirmed).

What is Chemed Corporation (CHE) earnings time?

Chemed Corporation (CHE) earnings time is at Oct 29, 2025, After Close (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is CHE EPS forecast?

CHE EPS forecast for the fiscal quarter 2025 (Q3) is 5.36.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing